Emma Reeve
CIK 1680329 · Chief Financial Officer · last filed 2026-06-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$763.5K
Companies
6
Total Filings
56
Lifetime Open-Market Net
-$10.27M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WHWK | Director | — | $4.47 | — | $0 | 2 | 2026-06-15 |
| PTCT | Director | 10,666 | $71.58 | $763.5K | -$6.12M | 18 | 2026-01-06 |
| Whitehawk Therapeutics, Inc. (AADI) Delisted | Director | — | $2.05 | — | $0 | 4 | 2024-06-14 |
| EDIT | Director | — | $2.83 | — | $0 | 4 | 2024-06-03 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | Chief Financial Officer | 6,260 | $33.99 | $212.8K | -$4.16M | 16 | 2021-02-23 |
| PAREXEL INTERNATIONAL CORP (PRXL) Delisted | Corp. VP & Interim CFO | 8,468 | — | — | $0 | 1 | 2016-12-09 |
Recent Filings · Page 3 of 6
56 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-06-20 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-05 | EDIT | Grant (A) | — | $0 | EDGAR |
| 2023-05-24 | PTCT | Mixed | — | -$255.5K | EDGAR |
| 2023-05-23 | PTCT | Notice (144) | −2,652 | -$157.9K | EDGAR |
| 2023-05-22 | PTCT | Notice (144) | −7,116 | -$423.6K | EDGAR |
| 2023-04-25 | PTCT | Sell (S) | −4,328 | -$238.3K | EDGAR |
| 2023-04-21 | PTCT | Notice (144) | −4,328 | -$238.3K | EDGAR |
| 2023-01-09 | PTCT | Grant (A) | +4,000 | $0 | EDGAR |
| 2022-06-17 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-13 | EDIT | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.